Profiling of the renal kinome: A novel tool to identify protein kinases involved in angiotensin II-dependent hypertensive renal damage

American Journal of Physiology - Renal Physiology

Volumn 293, Issue 1, 2007, Pages

  De Borst, Martin H ^a   Diks, Sander H ^a   Bolbrinker, Juliane ^b   Schellings, Mark W ^c   Van Dalen, Mario B A ^a   Peppelenbosch, Maikel P ^a   Kreutz, Reinhold ^b   Pinto, Yigal M ^c   Navis, Gerjan ^a   Van Goor, Harry ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Array; Protein kinase; Ren2; Signal transduction

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE; RAMIPRIL; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LYSATE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; HOMOZYGOSITY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INCUBATION TIME; ISOTOPE LABELING; KIDNEY FIBROSIS; KIDNEY INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; RAT; RENOVASCULAR HYPERTENSION; WESTERN BLOTTING; ANIMAL; BLOOD PRESSURE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENOME; KIDNEY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOME; HYPERTENSION, RENAL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KIDNEY; MALE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, INSULIN; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 34548039258     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00367.2006     Document Type: Article

References (36)

1. Adhikary L, Chow F, Nikolic-Paterson DJ, Stambe C, Dowling J, Atkins RC, Tesch GH. Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 47: 1210-1222, 2004.
2. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402, 1997.
3. Araki T, Nawa H, Neel BG. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem 278: 41677-41684, 2003.
4. Bailey JL, Zheng B, Hu Z, Price SR, Mitch WE. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol 17: 1388-1394, 2006.
5. Blendea MC, Jacobs D, Stump CS, McFarlane SI, Ogrin C, Bahtyiar G, Stas S, Kumar P, Sha Q, Ferrario CM, Sowers JR. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab 288: E353-E359, 2005.
6. Bolbrinker J, Markovic S, Wehland M, Melenhorst WB, van Goor H, Kreutz R. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension. J Pharmacol Exp Ther 316: 8-16, 2006.
7. Bunemann M, Hosey MM. G-protein coupled receptor kinases as modulators of G-protein signalling. J Physiol 517: 5-23, 1999.
8. De Borst MH, Navis G, de Boer RA, Huitema S, Vis LM, van Gilst WH, van Goor H. Specific MAP-kinase blockade protects against renal damage in homozygous TGR(mRen2)27 rats. Lab Invest 83: 1761-1770, 2003.
9. De Borst MH, Wassef L, Kelly DJ, van Goor H, Navis G. Mitogen activated protein kinase signaling in the kidney: target for intervention? Signal Transduct 6: 32-53, 2006.
10. Diks SH, Kok K, O'Toole T, Hommes DW, van Dijken P, Joore J, Peppelenbosch MP. Kinome profiling for studying lipopolysaccharide signal transduction in human peripheral blood mononuclear cells. J Biol Chem 279: 49206-49213, 2004.
11. Gros R, Chorazyczewski J, Meek MD, Benovic JL, Ferguson SS, Feldman RD. G-Protein-coupled receptor kinase activity in hypertension : increased vascular and lymphocyte G-protein receptor kinase-2 protein expression. Hypertension 35: 38-42, 2000.
12. Holness MJ, Sugden MC. The impact of genetic hypertension on insulin secretion and glucoregulatory control in vivo: studies with the TGR(mRen2)27 transgenic rat. J Hypertens 16: 369-376, 1998.
13. Iaccarino G, Rockman HA, Shotwell KF, Tomhave ED, Koch WJ. Myocardial overexpression of GRK3 in transgenic mice: evidence for in vivo selectivity of GRKs. Am J Physiol Heart Circ Physiol 275: H1298-H1306, 1998.
14. Jafari P, Azuaje F. An assessment of recently published gene expression data analyses: reporting experimental design and statistical factors. BMC Med Inform Decis Mak 6: 27, 2006.
15. Johnson SA, Hunter T. Kinomics: methods for deciphering the kinome. Nat Methods 2: 17-25, 2005.
16. Kinnick TR, Youngblood EB, O'Keefe MP, Saengsirisuwan V, Teachey MK, Henriksen EJ. Modulation of insulin resistance and hypertension by voluntary exercise training in the TG(mREN2)27 rat. J Appl Physiol 93: 805-812, 2002.
17. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, Lefkowitz RJ. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a β ARK inhibitor. Science 268: 1350-1353, 1995.
18. Kruszynska YT, Halban PA, Kahn CR, White MF. Activation of liver and muscle insulin receptor tyrosine kinase activity during in vivo insulin administration in rats. Diabetologia 33: 77-83, 1990.
19. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 11: 867-874, 2005.
20. Linz W, Wohlfart P, Schoelkens BA, Becker RH, Malinski T, Wiemer G. Late treatment with ramipril increases survival in old spontaneously hypertensive rats. Hypertension 34: 291-295, 1999.
21. Lowenberg M, Tuynman J, Scheffer M, Verhaar A, Vermeulen L, van Deventer S, Hommes D, Peppelenbosch M. Kinome analysis reveals nongenomic glucocorticoid receptor-dependent inhibition of insulin signaling. Endocrinology 147: 3555-3562, 2006.
22. Masaki T, Stambe C, Hill PA, Dowling J, Atkins RC, Nikolic-Paterson DJ. Activation of the extracellular-signal regulated protein kinase pathway in human glomerulopathies. J Am Soc Nephrol 15: 1835-1843, 2004.
23. Meguid El NA, Bello AK. Chronic kidney disease: the global challenge. Lancet 365: 331-340, 2005.
24. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 38: 635-638, 2001.
25. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M, Katagiri H, Fukushima Y, Kikuchi M, Noguchi N, Aburatani H, Komuro I, Fujita T. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40: 872-879, 2002.
26. Ohashi R, Nakagawa T, Watanabe S, Kanellis J, Almirez RG, Schreiner GF, Johnson RJ. Inhibition of p38 mitogen-activated protein kinase augments progression of remnant kidney model by activating the ERK pathway. Am J Pathol 164: 477-485, 2004.
27. Pals-Rylaarsdam R, Hosey MM. Two homologous phosphorylation domains differentially contribute to desensitization and internalization of the m2 muscarinic acetylcholine receptor. J Biol Chem 272: 14152-14158, 1997.
28. Rao RH. Effects of angiotensin II on insulin sensitivity and fasting glucose metabolism in rats. Am J Hypertens 7: 655-660, 1994.
29. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116: 288-296, 2006.
30. Rojas M, Yao S, Lin YZ. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 271: 27456-27461, 1996.
31. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 346: 683-693, 2002.
32. Schellings MW, Baumann M, van Leeuwen RE, Duisters RF, Janssen SH, Schroen B, Peutz-Kootstra CJ, Heymans S, Pinto YM. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 47: 467-474, 2006.
33. Stambe C, Atkins RC, Hill PA, Nikolic-Paterson DJ. Activation and cellular localization of the p38 and JNK MAPK pathways in rat crescentic glomerulonephritis. Kidney Int 64: 2121-2132, 2003.
34. Stambe C, Atkins RC, Tesch GH, Masaki T, Schreiner GF, Nikolic-Paterson DJ. The role of p38α mitogen-activated protein kinase activation in renal fibrosis. J Am Soc Nephrol 15: 370-379, 2004.
35. Stambe C, Nikolic-Paterson DJ, Hill PA, Dowling J, Atkins RC. p38 Mitogen-activated protein kinase activation and cell localization in human glomerulonephritis: correlation with renal injury. J Am Soc Nephrol 15: 326-336, 2004.
36. Tzatsos A, Kandror KV. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 26: 63-76, 2006.